While there is a path to injectable PrEP becoming available in the next five years, the widespread use of injectables to treat people living with HIV in low- and middle-income countries is unlikely in the near future. The combination of injectable cabotegravir and rilpivirine has only been approved by a handful of countries, it’s not clear whether rilpivirine will be available as a generic, and the regimen has complexities which make it less attractive than the preferred oral regimens.
But injectable HIV treatment could have a future in the global south, particularly when other long-acting products are developed, experts said at the 12th International AIDS Society Conference on HIV Science (IAS 2023).
Read the full story at Aidsmap.
Source : Aidsmap
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.